Trump’s former nominee to lead the U.S. drug agency promised a new safety review of abortion pills after pressure from Senator Hawley

Senator Josh Hawley urges federal action and supervision on mifepristone.

Dr. Heidi Overton, whose nomination to lead the Food and Drug Administration was later withdrawn, had agreed to set firm deadlines and clear standards for a safety review of mifepristone, Sen. Josh Hawley’s office said Friday.

Hawley, a Missouri Republican on the Senate Health, Education, Labor and Pensions Committee, has spent months seeking answers from federal health officials about delays to the review.

“These are major pro-life wins that help ensure a robust study and the potential reinstatement of critical safeguards on the abortion drug that President Biden stripped away,” Hawley said. He added that he expects the FDA to follow through, and that any future nominee for FDA commissioner would need to make the same commitment to earn his support.

The White House withdrew Overton’s nomination a day before a Senate committee was scheduled to vote on it. President Donald Trump had praised the physician and White House adviser as a “ROCKSTAR” when he selected her in August to replace Marty Makary, who resigned in May.

Hawley’s office said the administration had promised to complete a broad mifepristone safety study by March 2027. The FDA would then make any regulatory changes supported by the findings by September 2027. The updated safety rules would cover both brand-name mifepristone and generic versions.

The proposed review would examine Medicaid and commercial health data from before and after the Biden administration removed certain restrictions. Federal oversight of the medication has faced ongoing scrutiny since 2023, when the administration ended requirements for in-person doctor visits and in-person dispensing.

The FDA’s review has been delayed repeatedly, despite earlier assurances that a study would be released in 2025. Critics have raised concerns that important data could be left out.

In a questionnaire submitted to the Senate committee before her nomination was withdrawn, Overton wrote that the FDA intended to complete its review quickly, using appropriate data and qualified experts, and to make the scientific basis and findings public as fully as the law allows.

“If confirmed, I would support completing that work as expeditiously as practicable while preserving the integrity of the scientific review,” she wrote.

In March, Hawley called on fellow Republicans to support legislation banning mifepristone. He argued that the drug is dangerous to women as well as fatal to unborn children, and criticized drug companies for profiting from its distribution while facing limited liability. He said Congress could no longer ignore the risks.

Facebook
Twitter
LinkedIn
Reddit
Telegram
WhatsApp

Related News